Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 3
2010 2
2011 4
2012 3
2013 4
2014 1
2015 3
2016 4
2017 6
2018 6
2019 6
2020 2
2021 2
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

42 results
Results by year
Filters applied: . Clear all
Page 1
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial.
Antoniotti C, Rossini D, Pietrantonio F, Catteau A, Salvatore L, Lonardi S, Boquet I, Tamberi S, Marmorino F, Moretto R, Ambrosini M, Tamburini E, Tortora G, Passardi A, Bergamo F, Kassambara A, Sbarrato T, Morano F, Ritorto G, Borelli B, Boccaccino A, Conca V, Giordano M, Ugolini C, Fieschi J, Papadopulos A, Massoué C, Aprile G, Antonuzzo L, Gelsomino F, Martinelli E, Pella N, Masi G, Fontanini G, Boni L, Galon J, Cremolini C; GONO Foundation Investigators. Antoniotti C, et al. Among authors: kassambara a. Lancet Oncol. 2022 Jul;23(7):876-887. doi: 10.1016/S1470-2045(22)00274-1. Epub 2022 May 27. Lancet Oncol. 2022. PMID: 35636444 Clinical Trial.
Analysis of Global Gene Expression Profiles.
Kassambara A, Moreaux J. Kassambara A, et al. Methods Mol Biol. 2018;1792:157-166. doi: 10.1007/978-1-4939-7865-6_11. Methods Mol Biol. 2018. PMID: 29797258
Characterization of human FCRL4-positive B cells.
Jourdan M, Robert N, Cren M, Thibaut C, Duperray C, Kassambara A, Cogné M, Tarte K, Klein B, Moreaux J. Jourdan M, et al. Among authors: kassambara a. PLoS One. 2017 Jun 21;12(6):e0179793. doi: 10.1371/journal.pone.0179793. eCollection 2017. PLoS One. 2017. PMID: 28636654 Free PMC article.
PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs.
Herviou L, Kassambara A, Boireau S, Robert N, Requirand G, Müller-Tidow C, Vincent L, Seckinger A, Goldschmidt H, Cartron G, Hose D, Cavalli G, Moreaux J. Herviou L, et al. Among authors: kassambara a. Clin Epigenetics. 2018 Oct 3;10(1):121. doi: 10.1186/s13148-018-0554-4. Clin Epigenetics. 2018. PMID: 30285865 Free PMC article.
DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells.
Bruyer A, Maes K, Herviou L, Kassambara A, Seckinger A, Cartron G, Rème T, Robert N, Requirand G, Boireau S, Müller-Tidow C, Veyrune JL, Vincent L, Bouhya S, Goldschmidt H, Vanderkerken K, Hose D, Klein B, De Bruyne E, Moreaux J. Bruyer A, et al. Among authors: kassambara a. Br J Cancer. 2018 Apr;118(8):1062-1073. doi: 10.1038/s41416-018-0025-x. Epub 2018 Mar 2. Br J Cancer. 2018. PMID: 29500406 Free PMC article.
The hydroxymethylome of multiple myeloma identifies FAM72D as a 1q21 marker linked to proliferation.
Chatonnet F, Pignarre A, Sérandour AA, Caron G, Avner S, Robert N, Kassambara A, Laurent A, Bizot M, Agirre X, Prosper F, Martin-Subero JI, Moreaux J, Fest T, Salbert G. Chatonnet F, et al. Among authors: kassambara a. Haematologica. 2020 Mar;105(3):774-783. doi: 10.3324/haematol.2019.222133. Epub 2019 Jun 20. Haematologica. 2020. PMID: 31221779 Free PMC article.
42 results